A publication clause is the single most negotiated provision in an industry-sponsored research agreement, and it is where a university’s commitment to open dissemination most directly meets a sponsor’s commercial and confidentiality interests. Almost every sponsored research agreement (SRA) a research contracts office sees will contain some version of a publication delay or review clause. Very few institutions reject the concept outright — a brief, defined review period is standard practice on both sides of the table. What separates an acceptable clause from one a university’s general counsel and research office will push back on, or refuse, is not whether a delay exists at all, but its scope, duration, and who ultimately controls the decision to publish.
This guide sets out the terms research administrators, technology transfer offices, and principal investigators can expect to see in a publication clause, which variants are considered standard and negotiable, and which cross a line most US and UK research institutions treat as non-negotiable.
Why Sponsored Research Agreements Include a Publication Clause at All
A publication clause exists to reconcile two legitimate but competing interests. The university’s position, grounded in academic freedom and (for many institutions) accreditation and tenure norms, is that faculty must retain the right to publish their research results. The sponsor’s position is that a paper submitted for publication becomes public the moment it is posted, indexed, or presented — and public disclosure can permanently damage two things a commercial sponsor cares about: patent rights and trade secrets.
Two distinct sponsor interests drive most delay requests, and they call for different clause language:
- Patent protection. In the United States, an inventor’s own public disclosure starts a strict one-year clock on domestic filing and can destroy patent rights outright in most jurisdictions outside the US, which apply an absolute-novelty standard with no grace period. A sponsor (or the university’s own tech transfer office, on a jointly-owned invention) needs a review window to screen a manuscript for undisclosed inventions and file a provisional patent application before the paper becomes prior art. See CASRAI’s guide to 35 U.S.C. 102 novelty and invention-disclosure timing for how the statutory clock actually works.
- Confidential information. A sponsor may share its own background IP, unpublished data, or proprietary methods with the university team under a companion confidentiality agreement (NDA). The publication clause is the mechanism for the sponsor to flag and request removal of its own confidential information from a manuscript before submission — not to control the university’s own research findings.
The Line Universities Actually Draw: “Review” vs. “Veto”
The single most consistent principle across US research-university contracting guidance is that a sponsor may have a right to review a manuscript before submission, but not a right to approve it. The University of Texas System’s Publication Clause Checklist for Sponsored Research and Clinical Trial Agreements states this explicitly: draft language granting the sponsor “approval,” “prior written consent,” or any right that would let the sponsor deny public disclosure of the results should be struck and replaced with “review” — the institution must preserve its own, unconditional right to eventually publish.
In practice this means research offices will typically accept a clause that lets the sponsor comment, flag confidential information, and request a defined delay to file for patent protection, but will reject any clause conditioning publication on the sponsor’s sign-off, editorial approval of content, or unilateral right to suppress unfavorable results. The distinction sounds semantic; contractually it is not — it is the difference between a scheduling delay and a sponsor holding a permanent veto over what becomes part of the scientific record.
What’s Standard and Negotiable
Routine review windows: 30 to 60 days
A short window for the sponsor to read a manuscript before it is submitted for publication is standard and rarely contested. Guidance from research-university counsel offices and template agreements published by AUTM converge on roughly 30 to 60 days as the normal range for this first-look review period, running from the date the university provides the sponsor a copy of the manuscript intended for submission.
A capped extension to protect patent rights
If the sponsor’s review turns up a potentially patentable invention, most institutions will accept an additional, separately-capped delay — typically 30 to 90 days — solely for the purpose of preparing and filing a patent application (usually a lower-cost provisional application that preserves priority while the parties negotiate a full filing). This second delay should be tied explicitly to patent filing, not offered as a general-purpose extension the sponsor can invoke for any reason, and the total combined delay (review plus patent extension) is a figure research offices track and cap, not an open-ended runway.
Removing the sponsor’s own confidential information
A clause that lets the sponsor identify and request removal of its own proprietary information — data, methods, or materials the sponsor supplied under a companion confidentiality agreement — before submission is standard and generally accepted, since it does not touch the university’s own results. It should be cross-referenced against, not left in conflict with, the agreement’s separate confidentiality clause.
What Universities Generally Will Not Accept
- Sponsor approval or consent rights. Any language requiring the sponsor’s “approval,” “consent,” or right to “authorize” publication, rather than merely review it.
- Indefinite or undefined delay. A clause with no outside time limit, or one where the sponsor can renew or extend the delay at will, is treated as an unacceptable de facto veto rather than a scheduling accommodation.
- Removal of unfavorable or negative results. A clause permitting the sponsor to require deletion of data or conclusions it dislikes — as opposed to genuinely confidential sponsor information — conflicts directly with research-integrity norms and is a standard rejection point.
- Editorial or authorship control. Any right for the sponsor to dictate content, tone, or who is credited as an author crosses into ghostwriting and honorary-authorship territory; see CASRAI’s guide on industry-sponsored research authorship for how this is normally handled instead.
- Blanket restrictions on student theses and dissertations. A clause that would delay a graduate student’s thesis or dissertation defense and filing beyond the institution’s own degree timelines is a frequent flashpoint; most institutions carve students out of, or separately cap, any delay that would affect degree progress.
- Perpetual confidentiality of the SRA’s existence or general subject matter. Distinct from protecting specific data, a clause barring the university from ever acknowledging the relationship or the general research area is generally rejected as incompatible with academic transparency norms.
Multi-Site Studies and Clinical Trial Agreements: A Different Calculus
Multi-site and clinical research raise a variant of the same problem: a sponsor coordinating a trial across many sites has a legitimate interest in a single, coordinated first publication of the pooled results, rather than one site publishing early and undermining the joint analysis. Per the UT System checklist, acceptable clauses in this setting cap the sponsor’s right to publish (or control the timing of) joint multi-site results to roughly 18 to 24 months from study completion or database lock — and if the sponsor has not published within that window, the site’s independent publication right reverts. This is a materially different, longer timeframe than the 30-to-90-day windows typical of a single-site basic-research SRA, and it should not be confused with them; see CASRAI’s entries on the clinical trial agreement (CTA) and the model clinical trial agreement (mCTA) for how CTAs structure this and related terms.
Federal Grants Look Different From Industry Contracts
Publication delay clauses are overwhelmingly an industry-sponsored-research issue, not a federal-grant one. A federal grant’s terms and conditions generally do not give the funding agency a right to review or delay publication of results — the Bayh-Dole Act (35 U.S.C. 200–212), which governs inventions made under federally funded research, addresses invention disclosure, election of title, and the government’s retained license and march-in rights, but does not grant the funding agency editorial or publication-timing control over the resulting papers. Publication-clause negotiation belongs almost entirely to the pre-award, contracts-negotiation stage of an industry or foundation-sponsored agreement, not to standard federal grant administration.
Export Control: A Separate, Non-Negotiable Category of Delay
Distinct from commercially-motivated review, some sponsored agreements — particularly in defense-adjacent or dual-use fields — include a clause tied to export control screening under ITAR and the EAR. Where research is genuinely subject to export-control restrictions (rather than the more common case of fundamental research that qualifies for the public-domain/fundamental-research exclusion), a delay tied to an export-control review is a legal compliance requirement, not a negotiated commercial accommodation, and universities generally treat it differently from a sponsor-convenience delay — it cannot simply be negotiated away, though scoping which specific projects actually trigger it is very much a negotiation.
How Research Offices Actually Negotiate These Clauses
In practice, the negotiation runs through the institution’s sponsored-programs or research-contracts office, often in coordination with the technology transfer office when patentable subject matter is likely. A few practical patterns are worth knowing:
- Many institutions maintain their own standard publication-clause language (a “fallback” position) and will only deviate from it with documented sign-off, which is why sponsor-drafted language granting approval rights is so often flagged immediately rather than negotiated line by line.
- Model agreement libraries reduce friction on this exact clause. The UK’s Lambert Toolkit, for example, offers several pre-negotiated model collaboration agreements with different publication and IP allocations already built in, so parties can select a starting model rather than drafting the clause from scratch.
- Investigators should be looped in before a longer-than-standard delay is accepted — a delay extension that is invisible to the actual researcher until a manuscript is ready to submit is a common source of late-stage conflict.
- Where the invention side of the clause matters, a timely invention disclosure submitted well before the manuscript is finalized gives the technology transfer office room to work within the standard review windows rather than needing to request an extension; see also the consequences described in CASRAI’s guide on a missed invention disclosure deadline.
Frequently Asked Questions
Is a publication delay clause the same as a publication veto?
No, and the distinction is the entire point of this guide. A properly drafted delay clause gives the sponsor a time-limited window to review a manuscript and request removal of its own confidential information or a short extension to file for patent protection. A veto gives the sponsor a right to approve, consent to, or block publication outright. Universities routinely accept the former and reject the latter.
What is a typical total delay, combining review and patent-filing extensions?
Most single-site, non-clinical SRAs land in the range of 30 to 60 days for routine review, with a further capped 30 to 90 days available specifically to prepare a patent filing if the review surfaces a patentable invention — giving a realistic combined ceiling in the neighborhood of 60 to 150 days in cases where both apply, not an indefinite hold.
Can a sponsor require authorship changes as part of its review?
Reviewing for accuracy and flagging confidential information is standard; dictating who is listed as an author, or requiring credit for individuals who did not meet authorship criteria, is not. This is treated as a research-integrity issue distinct from the publication-timing clause itself.
Do these clauses apply the same way to a student’s thesis or dissertation?
Not usually without modification. Because a thesis or dissertation is tied to a degree timeline the university does not control unilaterally, most institutions negotiate a carve-out or separate, shorter cap for student work so a sponsor’s review period cannot delay a defense or degree conferral.
Why do multi-site clinical trials get a much longer delay window than other sponsored research?
Because the sponsor’s legitimate interest is coordinating one pooled, scientifically sound publication across many sites rather than protecting a single invention or dataset. That coordination interest is time-consuming in a way patent filing is not, which is why clinical multi-site agreements commonly allow an 18-to-24-month window rather than the 30-to-90-day range typical elsewhere — provided the sponsor’s right reverts to the site if it is not exercised within that window.
